Home › Funds › ORBIMED ADVISORS LLC › EWTX
ORBIMED ADVISORS LLC position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
ORBIMED ADVISORS LLC reported holding 15,518,492 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$630.5M, representing 12.68% of its reported portfolio and ranking #1 among its reported holdings. ORBIMED ADVISORS LLC has disclosed EWTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's EWTX position evolved
ORBIMED ADVISORS LLC first disclosed a stake in EWTX in Q3 2023 at 14,567,176 shares (US$83.5M). The position peaked in Q2 2026 at 15,518,492 shares, worth US$630.5M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 15,518,492 shares valued at US$630.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 14.57M | $83.47M | New |
| Q4 2023 | 14.57M | $159.36M | Hold |
| Q1 2024 | 15.02M | $274.00M | Add |
| Q2 2024 | 15.02M | $270.54M | Hold |
| Q3 2024 | 15.02M | $400.93M | Hold |
| Q4 2024 | 15.02M | $401.08M | Hold |
| Q1 2025 | 15.02M | $330.48M | Hold |
| Q2 2025 | 15.52M | $203.45M | Add |
| Q3 2025 | 15.52M | $251.71M | Hold |
| Q4 2025 | 15.52M | $385.09M | Hold |
| Q1 2026 | 15.52M | $488.83M | Hold |
| Q2 2026 | 15.52M | $630.52M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in EWTX — the largest reported positions include Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M), Novo Holdings A/S (US$217.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- Paradigm Biocapital Advisors LP 10.22M sh · $415.05M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 8.39M sh · $341.00M · Q2 2026
- Novo Holdings A/S 5.35M sh · $217.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.73M sh · $192.12M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.37M sh · $177.71M · Q2 2026
- BAKER BROS. ADVISORS LP 3.70M sh · $150.40M · Q2 2026
- Siren, L.L.C. 3.18M sh · $129.39M · Q2 2026
- Cormorant Asset Management, LP 2.51M sh · $101.98M · Q2 2026
- Integral Health Asset Management, LLC 2.00M sh · $81.26M · Q2 2026
- BRAIDWELL LP 2.00M sh · $81.14M · Q2 2026
- MPM BioImpact LLC 1.62M sh · $65.85M · Q2 2026
- First Light Asset Management, LLC 1.10M sh · $44.50M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held EWTX?
ORBIMED ADVISORS LLC has disclosed EWTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in EWTX?
As of Q2 2026, ORBIMED ADVISORS LLC holds 15.52M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $630.52M, representing 12.68% of its reported portfolio and ranking #1.
Has ORBIMED ADVISORS LLC been buying or selling EWTX?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in EWTX. The position peaked in Q2 2026 at 15.52M shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.